Jonas Bergquist

Jonas Bergquist, MD, PhD., Associate Professor of Clinical Neuroscience at the Sahlgrenska University Hospital and Gothenburg University, Sweden. In 1999, he became a Researcher in Uppsala University, Sweden. In 2005, he was appointed the Chaired Professor of Analytical Chemistry and Neurochemistry, heading the Bergquist group at the Department of Chemistry, Biomedical Centre, Uppsala University. Since 2011, he is an Adjunct Professor of Pathology at the University of Utah, Salt Lake City, USA, and since 2015, a Professor of Precision Medicine, Binzhou Medical University, China.

Research interests: various neurodegenerative diseases such as Parkinson's, Alzheimer's, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS); his research "involves methods to measure substances that can act as biomarkers for early diagnosis and contribute to the understanding of what initiates the disease process... [and] measure not only the individual substances but also seek patterns and monitor how they change during illness,... [the Bergquist group's] specialty is the analysis of cerebrospinal fluid and its chemical composition."

Talks and Interviews

 * 2015, Speaker at the 10th Invest in ME International ME Conference - (no speech title given) DVD available

Research Studies on ME/CFS

 * 2011, Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome"Abstract:'Neurologic Post Treatment Lyme disease (nPTLS) and Chronic Fatigue (CFS) are syndromes of unknown etiology. They share features of fatigue and cognitive dysfunction, making it difficult to differentiate them. Unresolved is whether nPTLS is a subset of CFS...METHODS:Pooled cerebrospinal fluid (CSF) samples from nPTLS patients, CFS patients, and healthy volunteers were comprehensively analyzed using high-resolution mass spectrometry (MS), coupled with immunoaffinity depletion methods to reduce protein-masking by abundant proteins...CONCLUSIONs:nPTLS and CFS have distinguishing CSF protein complements. Each condition has a number of CSF proteins that can be useful in providing candidates for future validation studies and insights on the respective mechanisms of pathogenesis. Distinguishing nPTLS and CFS permits more focused study of each condition, and can lead to novel diagnostics and therapeutic interventions.'"